Table 4.
Predictors of progression-free survival.
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| Age (y) | 0.997 | 0.970-1.025 | 0.827 | |||
| Gender | ||||||
| Male | 1 | |||||
| Female | 0.644 | 0.368-1.128 | 0.124 | |||
| Hepatitis types | ||||||
| None | 1 | |||||
| B | 1.485 | 0.753-2.928 | 0.254 | |||
| C | 0.945 | 0.431-2.074 | 0.889 | |||
| AFP level before treatment | 1.000 | 1.000-1.000 | 0.286 | |||
| AFP level after treatment | 1.000 | 1.000-1.000 | 0.302 | |||
| Child-Pugh class | ||||||
| A | 1 | 1 | ||||
| B | 1.641 | 0.951-2.830 | 0.075 | 1.887 | 1.074-3.315 | 0.027 |
| BCLC stage | ||||||
| A | 1 | |||||
| B | 0.648 | 0.378-1.110 | 0.114 | |||
| Number of tumors | ||||||
| 2 | 1 | |||||
| 3 | 1.009 | 0.619-1.645 | 0.971 | |||
| Largest tumor diameter | 1.083 | 0.924-1.270 | 0.325 | |||
| Treatment options | ||||||
| Combined treatment | 1 | 1 | ||||
| TACE only | 1.660 | 1.064-2.591 | 0.026 | 1.807 | 1.146-2.850 | 0.011 |
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization.